SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Morepen Laboratories shines on the buzz of entering into partnership with Vesale Pharma

09 Nov 2017 Evaluate

Morepen Laboratories is currently trading at Rs. 18.25, up by 0.45 points or 2.53% from its previous closing of Rs. 17.80 on the BSE.

The scrip opened at Rs. 18.60 and has touched a high and low of Rs. 18.70 and Rs. 18.20 respectively. So far 109698 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 25.10 on 09-Nov-2016 and a 52 week low of Rs. 14.80 on 11-Aug-2017.

Last one week high and low of the scrip stood at Rs. 18.95 and Rs. 16.85 respectively. The current market cap of the company is Rs. 820.93 crore.

The promoters holding in the company stood at 34.54%, while institutions and non-institutions held 18.80% and 46.66% respectively.

In a bid to aggressively tap the growing probiotics market in India, Morepen Laboratories has reportedly entered into partnership with Belgium's Vesale Pharma. The move is expected to contribute Rs 100 crore to the Indian company's topline in five years. Moreover, the company will soon be launching four major probiotics developed by Vesale Pharma in the Indian market.

Morepen is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.

Morepen Laboratories Share Price

40.12 -0.06 (-0.15%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×